TITLE

ANOREXIGENIC DRUGS IN THE TREATMENT OF OBESITY: PAST, PRESENT AND FUTURE

AUTHOR(S)
┼×tefania, Todea; Gabriel, Hancu
PUB. DATE
January 2019
SOURCE
Acta Medica Marisiensis;2019 Supplement, Vol. 65, p69
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Obesity is a medical condition in which the subject carries an excess weight; and represents a great problem in modern society. Obesity is related to multiple reasons, including diet, lifestyle, pathological conditions, genetic factors or the use of certain medications. It can increase risks in developing health problems but losing weight can be sometimes a difficult and frustrating problem. Several treatment options are available, including regular exercise and dietary changes but also pharmacological treatment. Objective: The aim of the study is an evaluation of the actual state of anorexigenic medication, taking in consideration the controversies related to antiobesity drugs involving failures in clinical development and withdrawals due to adverse effects. Material and methods: Comparing several studies regarding pharmacokinetic, pharmacologic and pharmacotoxicologic profiles of certain drugs can be a solution and an important tool in understanding obesity pathology and the processes underlying its pharmacological treatment. Results: Although based on historical data we can state that anti-obesity medication failed to meet expectations, however in recent years an emergence of new therapeutic options can be observed. The aim of modern pharmacotherapy is to loose weight, but also to improve other associated pathologies such as diabetes, hyperlipidemia and cardiovascular diseases. Conclusions: Obesity represents a growing worldwide pandemic with high health and economic consequences. Pharmacotherapy combined with lifestyle changes are the current choices used to diminish the consequences of this pathological condition and its sequalae. However pharmacological treatment has a significant history of health risks, consequently new treatment pathways are a necessity and a challenge for modern medicine.
ACCESSION #
136920107

 

Related Articles

  • Lorcaserin: A novel antiobesity drug. Brashier, Dick B. S.; Sharma, A. K.; Navdeep Dahiya; Singh, S. K.; Anjan Khadka // Journal of Pharmacology & Pharmacotherapeutics;Apr-Jun2014, Vol. 5 Issue 2, p175 

    Obesity is a major co-morbidity with hypertension and diabetes mellitus. There are few drugs for treatment of obesity like orlistat and recentlty approved drug lorcaserin. Lorcaserin has serotonergic properties and acts as an anorectic. It may cause serious side effects, including serotonin...

  • THE NEW PRESCRIPTIONS.  // Marie Claire (US Edition);Oct2012, Vol. 19 Issue 10, p270 

    The article offers a preview on the two diet medications approved by the U.S. Food and Drug Administration (FDA), the Belviq and the combined phentermine and topiramate drug called Qsymia and another drug, the Contrave, which is to be reviewed by the agency after it was rejected in 2011.

  • Why Diet Drugs Can Be Diet Dangers. Murphy, Dee // Current Health 2;Dec2000, Vol. 27 Issue 4, p18 

    Explains the dangers of using diet pills and other weight loss preparations. INSET: Why Diet Claims: Fact or Fiction?.

  • Fen-Phen `wannabe's' crowding the weight-loss scene. Zied, Elisa S. // Environmental Nutrition;Dec97, Vol. 20 Issue 12, p2 

    Evaluates several drugs for weight reduction. Need for prescription for the combination drug phentermine and fluoxetine; Herbal origins of the Herbal Phen-Fen drug alternative; Promotion of various amino acid combinations for weight loss uses.

  • New anti-obesity drug is not for everyone.  // Mayo Clinic Health Letter;Aug1999, Vol. 17 Issue 8, p4 

    Reports on the use of the anti-obesity drug orlistat. Indications approved by the United States Food & Drug Administration; Differences from other diet drugs; Side effects; Precautionary measures in using the drug.

  • Oxedrine.  // Reactions Weekly;4/3/2010, Issue 1295/1296, p30 

    The article describes the case of a 24-year-old man who developed ST elevation myocardial infarction (STEMI) while taking oxedrine for weight loss.

  • Next generation of `diet pills' may offer hope for weight control. Hrabak, DeAnne // Environmental Nutrition;Nov94, Vol. 17 Issue 11, p1 

    Reports on health professionals' increasing focus on the use of prescription appetite suppressants or diet pills as a way to control weight permanently. Addition of diet pills to classic exercise/reduced-calorie/reduced-fat eating plans; Use of appetite suppressants in other drug treatments for...

  • Diet drugs: The next generation.  // Shape;Oct96, Vol. 16 Issue 2, p118 

    Presents a list of upcoming and US Food and Drug Administration-approved weight loss drugs. Therapeutic use; Side effects.

  • Who exactly should be taking these drugs?  // Shape;Oct96, Vol. 16 Issue 2, p118 

    Highlights the physiological effects of diet drugs, according to Pennington Biomedical Research Center executive director for science Donna Ryan. Side effects of appetite depressants; Health risks associated with obesity; Efficacy of drug pills for people with serious weight problems.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics